PsyRx
Drug Development Using Biological Bioreactor Technology
Company Overview
Snapshot
Founded in October 2019 by Asher Holzer, Asher Holtzer, Itay Hecht, and Kobi Buxdorf, PsyRx operates with 1–10 employees. The company has raised $3.48 million across four funding rounds. In November 2025, PsyRx went public on TASE through a reverse merger with CannaboTech.
Business overview
PsyRx is a pharmaceutical R&D company focused on developing biological API psilocybin and ibogaine using bioreactor technology. The company aims to be a leading producer of GMP-standard ibogaine and psilocybin for pharmaceutical, food supplement, and other product development. PsyRx is also developing a novel antidepressant drug that combines ibogaine with existing approved antidepressants, seeking to enhance efficacy and reduce side effects. It operates within the Health Tech & Life Sciences sector, specifically targeting the Drugs Discovery & Development and Pharmaceuticals markets.
Strategic signal
In November 2025, PsyRx completed a reverse merger with CannaboTech and went public on the TASE. This strategic move provides PsyRx with access to public markets, potentially accelerating its drug development initiatives for depression and addiction treatments, and signals a significant step towards commercialization and broader investor engagement for its psychedelic and ibogaine-based therapies.
Log in to access full profile ›Company Intelligence Q&A
- What was a significant corporate milestone for PsyRx in late 2025?
- In November 2025, PsyRx went public on the TASE through a reverse merger with CannaboTech, marking a key transition for the company.
- What is PsyRx's primary focus in drug development?
- PsyRx is focused on developing biological API psilocybin and ibogaine using bioreactor technology, aiming to produce GMP-standard ingredients for pharmaceutical and other applications. The company also aims to develop a revolutionary antidepressant drug based on a combination of ibogaine and existing approved antidepressants.
- When was PsyRx founded and by whom?
- PsyRx was founded in October 2019 by Asher Holzer, Asher Holtzer, Itay Hecht, and Kobi Buxdorf.
- What is the total capital raised by PsyRx?
- PsyRx has raised a total of $3.48 million across four funding rounds.
- What is the status of PsyRx's product development?
- PsyRx's product development is currently in the clinical trial stage. The company is developing a novel antidepressant drug combining ibogaine with existing antidepressants, aiming to enhance efficacy and reduce side effects.